PMC:7408073 / 100000-100961
Annnotations
LitCovid-PD-FMA-UBERON
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T1 | 124-139 | Body_part | denotes | digestive tract | http://purl.org/sig/ont/fma/fma317863 |
T2 | 168-173 | Body_part | denotes | bowel | http://purl.org/sig/ont/fma/fma7199 |
T3 | 629-634 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
T4 | 685-693 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
T5 | 829-837 | Body_part | denotes | capsules | http://purl.org/sig/ont/fma/fma85272 |
LitCovid-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T195 | 124-139 | Body_part | denotes | digestive tract | http://purl.obolibrary.org/obo/UBERON_0001555 |
T196 | 629-634 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
3477 | 249-253 | Gene | denotes | ACE2 | Gene:59272 |
3478 | 25-28 | Gene | denotes | MLN | Gene:4295 |
3479 | 3-9 | Species | denotes | humans | Tax:9606 |
3480 | 155-181 | Disease | denotes | Inflammatory bowel disease | MESH:D015212 |
3481 | 183-204 | Disease | denotes | gastritis and colitis | MESH:D005756 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T555 | 140-153 | Disease | denotes | inflammations | http://purl.obolibrary.org/obo/MONDO_0021166 |
T556 | 155-181 | Disease | denotes | Inflammatory bowel disease | http://purl.obolibrary.org/obo/MONDO_0005265 |
T557 | 183-192 | Disease | denotes | gastritis | http://purl.obolibrary.org/obo/MONDO_0004966 |
T558 | 197-204 | Disease | denotes | colitis | http://purl.obolibrary.org/obo/MONDO_0005292 |
LitCovid-PD-CLO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 3-9 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humans |
T2 | 59-65 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
T3 | 124-139 | http://purl.obolibrary.org/obo/UBERON_0001555 | denotes | digestive tract |
T4 | 258-259 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
T5 | 277-284 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | testing |
T6 | 629-634 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
T7 | 629-634 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
T8 | 811-817 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | active |
T9 | 851-852 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T3495 | 90-104 | Chemical | denotes | pharmaceutical | http://purl.obolibrary.org/obo/CHEBI_52217 |
T11 | 350-354 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
T72202 | 818-822 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
LitCovid-PD-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T1 | 140-153 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammations |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T484 | 86-254 | Sentence | denotes | Its pharmaceutical indication was for digestive tract inflammations (Inflammatory bowel disease, gastritis and colitis) that are correlated with overexpression of ACE2. |
T485 | 255-331 | Sentence | denotes | In a Phase I clinical testing up 14 days dosing, ORE1001 was well tolerated. |
T486 | 332-416 | Sentence | denotes | Subjects received drug (dosing up to 2100 mg) with no side adverse effects reported. |
T487 | 417-554 | Sentence | denotes | In particular, 47 subjects received single-dose from 2.1 to 2100 mg and 24 subjects received 14 day multiple doses from 50 mg to 1800 mg. |
T488 | 555-644 | Sentence | denotes | All doses were well tolerated, with no significant side effects including blood pressure. |
T489 | 645-802 | Sentence | denotes | Pharmacokinetics of orally administered capsules was consistent with once-daily dosing. (http://oreholdings.com/wp-content/uploads/2013/06/09.10.09-425.pdf). |
T490 | 803-961 | Sentence | denotes | 300 mg (active drug) oral capsules were used in a Phase Ib/IIa clinical trial that was, however, abandoned. (https://clinicaltrials.gov/ct2/show/NCT01039597). |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T162 | 155-181 | Phenotype | denotes | Inflammatory bowel disease | http://purl.obolibrary.org/obo/HP_0002037 |
T163 | 183-192 | Phenotype | denotes | gastritis | http://purl.obolibrary.org/obo/HP_0005263 |
T164 | 197-204 | Phenotype | denotes | colitis | http://purl.obolibrary.org/obo/HP_0002583 |